Genetic studies of neurodevelopmental disorders by Wincent, Josephine
 Institutionen för molekylär medicin och kirurgi 
Genetic studies of neurodevelopmental 
disorders 
 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska 
Institutet offentligen försvaras i Rolf Luft Auditorium,  
Karolinska Universitetssjukhuset, CMM L1:00 
Fredagen den 27 April, 2012, kl 09.00 
av 
Josephine Wincent 
 
Huvudhandledare:  
Docent Jacqueline Schoumans 
Karolinska Institutet 
Institutionen för molekylär medicin och kirurgi 
Lausanne University Hospital 
Department of medical genetics 
 
 
Bihandledare:  
Med. Dr. Britt-Marie Anderlid 
Karolinska Institutet 
Institutionen för molekylär medicin och kirurgi 
 
Professor Magnus Nordenskjöld 
Karolinska Institutet 
Institutionen för molekylär medicin och kirurgi 
 
Fakultetsopponent: 
Docent Charles Lee 
Harvard Medical School 
Department of pathology 
 
Betygsnämnd: 
Docent Ulrika von Döbeln 
Karolinska Institutet 
Institutionen för laboratoreimedicin 
 
Docent Jon Jonasson 
Linköpings Universitet 
Institutionen för klinisk och experimentell 
medicin 
 
Professor Thomas Sejersen 
Karolinska Institutet 
Institutionen för kvinnors och barns hälsa 
 
 
Stockholm 2012 
 
ABSTRACT 
 
Neurodevelopmental disorders (NDDs) constitute a heterogeneous group of disorders that adversely 
impacts a child’s behavioural and learning processes. Developmental delay (DD) and mental 
retardation are included among the NDDs and are frequently associated with a wide range of 
accompanying disabilities such as multiple congenital anomalies and dysmorphic features. Despite 
extensive clinical and laboratory investigation, the cause of the patient’s symptoms remains 
unknown in approximately half of the cases. For the children’s families this is often frustrating since 
an aetiological diagnosis not only gives an explanation of why the child has symptoms but may also 
provide better prognosis evaluation, adequate genetic counselling and enable prenatal diagnosis. In 
approximately 20% of patients, a clear genetic cause can be found, including both single-gene 
disorders and chromosomal disorders. 
In paper I a NIPBL and SMC1L1 mutation screening by direct sequencing and MLPA was 
performed in a group of nine index patients diagnosed with Cornelia de Lange syndrome (CdLS), 
which is characterized by severe mental and growth retardation and distinctive dysmorphic 
facial features. We identified seven NIPBL mutations and showed that a splice-site mutation lead to 
skipping of an exon. A clear genotype-phenotype correlation was not found. 
In paper II sequencing and MLPA analysis revealed 18 CHD7 mutations in 28 index patients 
with CHARGE syndrome. In addition, inherited variants were identified and clinical interpretation of 
these are discussed. Our results indicate that hypoplastic semicircular canals is not obligatory for a 
CHD7 mutation, although we agree that it is the most frequent and specific sign of CHARGE 
syndrome. A CHD7 mutation was found in a patient not fulfilling clinical criteria showing that also 
atypical patients benefit from testing.  
Paper I and II confirm that NIPBL and CHD7 are the main causative genes for CdLS and 
CHARGE syndrome respectively. However, in >30% of our patients no causal mutation could be 
detected. Whole genome-/exome sequencing might find new causative genes and/or mutations in 
non-coding sequences of known genes. 
The patient described in paper III had an 18.2 Mb de novo deletion of chromosome 11q13.4-
q14.3. By comparing his phenotype to the few previously described patients, we show that a 
common phenotype for patients with deletions in this region might be emerging, comprising mild-
moderate DD, a sociable personality and dysmorphic facial features.  
The implementation of high-resolution array-CGH over the last decade has enabled the 
genome-wide identification of submicroscopic copy number variations (CNVs) in patients with 
NDDs. In study IV we wanted to evaluate array-CGH as a diagnostic tool in our clinical laboratory. 
In the 160 investigated patients, 21 (13,1%) causal CNVs and 15 (9.4%) CNVs of unclear clinical 
significance were detected. Standard karyotyping had in seven cases failed to detect causal CNVs ≥5 
Mb, five of which were ≥10Mb, emphasizing that more reliable methods were needed to exclude 
CNVs in these patients. Array-CGH proved to be very useful and became recommended as the first 
step investigation for patients with idiopathic DD. However, increasing the resolution of a whole 
genome screen in the diagnostic setting has its drawback of detecting an increased number of CNVs 
of unclear clinical significance. 
In paper V we report on the clinical and molecular characterization of 16 individuals with 
distal 22q11.2 duplications. The patients displayed a variable phenotype, and many of the 
duplications were inherited (83%). The possible pathogenicity of these duplications is discussed and 
we conclude that it is likely that distal 22q11.2 duplications represent a susceptibility/risk locus for 
NDDs rather than being causal variants. Additional genetic, epigenetic or environmental factors are 
likely required to cause a phenotype. Five patients had additional CVNs of unclear clinical 
significance making a 2-hit event plausible.
 
Paper IV and V illustrate that the identification of CNVs of uncertain clinical significance puts 
new demands on genetic counselling and continuous research and submission of cases to databases 
are still important. 
Future challenges include how to deal with the interpretation of multiple rare variants in one 
individual and to find ways to estimate how great a risk factor certain CNVs, such as distal 22q11.2 
duplications, actually are for a phenotypic effect.  
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